Clinical Trials
50 trialsA Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
HBHL
University of Nebraska
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
FluBuATG
Dartmouth-Hitchcock Medical Center
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
University of Wisconsin, Madison
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Genentech, Inc.
Safety of Romiplostim (Nplate®) Following UCBT
Masonic Cancer Center, University of Minnesota
Symbenda Post-Marketing Surveillance (PMS)
Eisai Inc.
Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Analyses of Human Samples Collected in Clinical Trials
National Institutes of Health Clinical Center (CC)
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Chinese PLA General Hospital
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Institutes of Health Clinical Center (CC)
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
University of Wisconsin, Madison
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
University of Wisconsin, Madison
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Janssen Pharmaceutical K.K.
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
University of Illinois at Chicago
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
University of North Carolina, Chapel Hill
TCP
Etablissement Français du Sang
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
RV-405 LAL
Institut de Cancérologie de la Loire
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Research (Munich) GmbH
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
H. Lee Moffitt Cancer Center and Research Institute
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Novartis
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
University of Kansas Medical Center
Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias
Stanford University
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
National Institutes of Health Clinical Center (CC)
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
Assistance Publique - Hôpitaux de Paris
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
H. Lee Moffitt Cancer Center and Research Institute
MK0457 in Patients With Leukemia (0457-003)
Merck Sharp & Dohme LLC
ExCell
Gamida Cell -Teva Joint Venture Ltd.
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Mirati Therapeutics Inc.
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Merck Sharp & Dohme LLC
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Pharmacyclics LLC.
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
PCYC-04753
Pharmacyclics LLC.
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
Stanford University
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Study of Enzastaurin in Patients With Leukemia
Eli Lilly and Company
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
BioCryst Pharmaceuticals